当前位置：
X-MOL 学术
›
Adv. Healthcare Mater.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2018-01-19 , DOI: 10.1002/adhm.201701174 Darren Rodenhizer 1 , Teresa Dean 2 , Elisa D'Arcangelo 2 , Alison P. McGuigan 3
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2018-01-19 , DOI: 10.1002/adhm.201701174 Darren Rodenhizer 1 , Teresa Dean 2 , Elisa D'Arcangelo 2 , Alison P. McGuigan 3
Affiliation
|
Cancer prognosis remains a lottery dependent on cancer type, disease stage at diagnosis, and personal genetics. While investment in research is at an all‐time high, new drugs are more likely to fail in clinical trials today than in the 1970s. In this review, a summary of current survival statistics in North America is provided, followed by an overview of the modern drug discovery process, classes of models used throughout different stages, and challenges associated with drug development efficiency are highlighted. Then, an overview of the cancer hallmarks that drive clinical progression is provided, and the range of available clinical therapies within the context of these hallmarks is categorized. Specifically, it is found that historically, the development of therapies is limited to a subset of possible targets. This provides evidence for the opportunities offered by novel disease‐relevant in vitro models that enable identification of novel targets that facilitate interactions between the tumor cells and their surrounding microenvironment. Next, an overview of the models currently reported in literature is provided, and the cancer biology they have been used to explore is highlighted. Finally, four priority areas are suggested for the field to accelerate adoption of in vitro tumour models for cancer drug discovery.
中文翻译：
3D体外肿瘤模型的当前状况：哪些癌症标志可用于药物发现？
癌症的预后仍然取决于癌症类型，诊断时的疾病阶段以及个人遗传学。尽管对研究的投资达到了空前的高水平，但与1970年代相比，如今新药在临床试验中失败的可能性更大。在这篇综述中，提供了北美当前生存统计的摘要，然后概述了现代药物发现过程，在不同阶段使用的模型类别以及与药物开发效率相关的挑战。然后，概述了驱动临床进展的癌症标志，并对这些标志范围内的可用临床疗法进行了分类。具体而言，发现历史上疗法的发展仅限于可能靶标的子集。这提供了与疾病相关的新型体外模型提供的机会的证据，该模型能够鉴定促进肿瘤细胞与其周围微环境之间相互作用的新型靶标。接下来，概述了目前文献中报道的模型，并着重介绍了已用于探索的癌症生物学。最后，为该领域提出了四个优先领域，以加速采用体外肿瘤模型进行癌症药物发现。
更新日期：2018-01-19
中文翻译：
3D体外肿瘤模型的当前状况：哪些癌症标志可用于药物发现？
癌症的预后仍然取决于癌症类型，诊断时的疾病阶段以及个人遗传学。尽管对研究的投资达到了空前的高水平，但与1970年代相比，如今新药在临床试验中失败的可能性更大。在这篇综述中，提供了北美当前生存统计的摘要，然后概述了现代药物发现过程，在不同阶段使用的模型类别以及与药物开发效率相关的挑战。然后，概述了驱动临床进展的癌症标志，并对这些标志范围内的可用临床疗法进行了分类。具体而言，发现历史上疗法的发展仅限于可能靶标的子集。这提供了与疾病相关的新型体外模型提供的机会的证据，该模型能够鉴定促进肿瘤细胞与其周围微环境之间相互作用的新型靶标。接下来，概述了目前文献中报道的模型，并着重介绍了已用于探索的癌症生物学。最后，为该领域提出了四个优先领域，以加速采用体外肿瘤模型进行癌症药物发现。
京公网安备 11010802027423号